[Form 4] Inmune Bio, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Inmune Bio, Inc. (INMB)November 18, 2025, shareholders approved a one-time repricing of certain outstanding options granted under the company’s 2017, 2019 and 2021 stock incentive plans. The repricing reduced the exercise price of each affected option to $1.50 per share, which was the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on that date.

The Form 4 shows cancellations of existing stock options with higher exercise prices and the grant of replacement options at the new $1.50 exercise price for the same numbers of underlying shares and original expiration dates. All other terms of these options, including vesting schedules and overall terms, remain unchanged and continue to depend on the executive’s ongoing service with the company.

11/18/2025 - 05:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ellspermann Cory Randall

(Last) (First) (Middle)

C/O INMUNE BIO INC.

225 NE MIZNER BLVD., SUITE 640

(Street)

BOCA RATON FL 33432

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inmune Bio, Inc. [ INMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.91	11/18/2025		D(1)			75,000	(2)	11/24/2029	Common Stock	75,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		75,000		(2)	11/24/2029	Common Stock	75,000	(1)	75,000	D
Stock Option (right to buy)	$21.06	11/18/2025		D(1)			40,000	(2)	07/22/2031	Common Stock	40,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		40,000		(2)	07/22/2031	Common Stock	40,000	(1)	40,000	D
Stock Option (right to buy)	$7.92	11/18/2025		D(1)			30,000	(2)	03/20/2032	Common Stock	30,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		30,000		(2)	03/20/2032	Common Stock	30,000	(1)	30,000	D
Stock Option (right to buy)	$5.05	11/18/2025		D(1)			70,000	(2)	12/04/2034	Common Stock	70,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		70,000		(2)	12/04/2034	Common Stock	70,000	(1)	70,000	D
Stock Option (right to buy)	$9.92	11/18/2025		D(1)			30,000	(2)	05/13/2034	Common Stock	30,000	(1)	0	D
Stock Option (right to buy)	$1.5	11/18/2025		A(1)		30,000		(2)	05/13/2034	Common Stock	30,000	(1)	30,000	D

Explanation of Responses:

1. Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

2. This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

	/s/ Cory Randall Ellspermann	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Inmune Bio (INMB) disclose in this Form 4 filing?

Inmune Bio disclosed that its interim CFO, Cory Randall Ellspermann, had certain existing stock options repriced to a new exercise price, with the changes reported as option dispositions and new option grants on the same underlying share amounts.

What is the new exercise price of the repriced INMB stock options?

The affected stock options now have an exercise price of $1.50 per share, which represents the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on the repricing date.

When were the Inmune Bio (INMB) option repricing changes approved?

The option repricing became effective on November 18, 2025, when Inmune Bio’s stockholders approved a one-time repricing of certain outstanding stock options held under its equity incentive plans.

Which equity plans are involved in the INMB option repricing?

The repriced options were granted under Inmune Bio’s 2017 Stock Incentive Plan, 2019 Stock Incentive Plan, and Second Amended and Restated 2021 Stock Incentive Plan.

Did the vesting terms of the repriced INMB options change?

No. The company states that, apart from the new $1.50 exercise price, all other terms and conditions of the repriced options, including vesting schedules and overall terms, remain in full force and effect.

Whose options were affected by this INMB Form 4 transaction?

The Form 4 relates to stock options held by Cory Randall Ellspermann, who serves as Inmune Bio’s interim Chief Financial Officer and is listed as the sole reporting person on the filing.